News Sentiment

KLRS sentiment intelligence

Kalaris Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.44 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.5% over one week, +2.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -6.5% Price reacting lower
Trend fit Trend inactive 2.5% over four weeks
Fair value -73.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 31
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Stock Titan 7
TradingView 6
TradingKey 4
The Manila Times 3
simplywall.st 3
dars.gov.et 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 18
Analyst action 5
Deals and strategy 3
Regulatory and legal 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
The Manila Times Direct company coverage

Kalaris Appoints Laurie Keating to Board of Directors

Kalaris Therapeutics has announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. Keating, a highly experienced biotechnology executive, will bring extensive strategic, operational, and legal expertise to the board, aiding Kalaris in its ne

Tone
Positive 71/100
Event
Market update
Published
06 Jul 2026 20:40
Source
The Manila Times
Moomoo Direct company coverage

Press Release: Kalaris Appoints Laurie Keating to Board of Directors

The provided content is a placeholder document. Without access to the actual content, a summary cannot be generated. It is expected to be a press release announcing the appointment of Laurie Keating to the Board of Directors of Kalaris.

Tone
Positive 86/100
Event
Market update
Published
06 Jul 2026 19:43
Source
Moomoo
TradingView Direct company coverage

Price to book forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS

The article displays the "Price to book forward" for Kalaris Therapeutics, Inc. (NASDAQ: KLRS) on TradingView. It provides basic information about the company including its stock market listing and offers links to various financial data, news, and community features on the platfo

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 05:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS

This article mentions the enterprise value to EBITDA forward for Kalaris Therapeutics, Inc., traded on NASDAQ under the symbol KLRS. It appears to be a stub or a section from a financial data platform, providing a heading for a specific financial metric for the company.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 11:41
Source
TradingView
The Manila Times Direct company coverage

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics, Inc. announced the upcoming presentation of Phase 1a clinical data for TH103 at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. The presentation will detail the first-in-human evaluation of TH103, a dual-targeting VEGF/HSPG biologic fo

Tone
Positive 71/100
Event
Market update
Published
26 Jun 2026 17:10
Source
The Manila Times
TradingView Direct company coverage

Kalaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:KLRS)

This article provides an overview of Kalaris Therapeutics, Inc. (NASDAQ:KLRS) stock performance, financial data, and analyst forecasts. It details the current stock price, historical highs and lows, market capitalization, earnings per share, and revenue, alongside analyst price t

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 12:10
Source
TradingView
TradingView Direct company coverage

KLRS Forecast — Price Target — Prediction for 2027

This article provides a detailed forecast and analysis for Kalaris Therapeutics, Inc. (KLRS) stock, including analyst price targets, historical stock performance, and financial data. It covers current stock price, volatility, market capitalization, and upcoming earnings reports,

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 13:40
Source
TradingView
Investing.com India Direct company coverage

Kalaris to present Phase 1a data on retinal drug at ASRS meeting By Investing.com

Kalaris Therapeutics (NASDAQ:KLRS) announced it will present Phase 1a data for its investigational drug TH103, a dual-targeting biologic for neovascular age-related macular degeneration, at the American Society of Retina Specialists 2026 Annual Meeting. The company also stated th

Tone
Positive 66/100
Event
Regulatory and legal
Published
24 Jun 2026 01:10
Source
Investing.com India
Investing.com Nigeria Direct company coverage

Kalaris to present Phase 1a data on retinal drug at ASRS meeting

Kalaris Therapeutics (NASDAQ:KLRS) announced it will present Phase 1a data for its investigational drug TH103, a dual-targeting biologic for neovascular age-related macular degeneration, at the American Society of Retina Specialists 2026 Annual Meeting on July 17, 2026. The compa

Tone
Positive 67/100
Event
Regulatory and legal
Published
23 Jun 2026 23:10
Source
Investing.com Nigeria
Simply Wall Street Direct company coverage

Kalaris Therapeutics (Nasdaq:KLRS) - Stock Analysis

Kalaris Therapeutics (KLRS) is a clinical-stage biopharmaceutical company focused on treatments for retinal diseases. The company is currently unprofitable and has seen dilution of shares, but its lead asset, TH103, has shown positive Phase 1a data for neovascular Age-Related Mac

Tone
Positive 62/100
Event
Market update
Published
21 Jun 2026 23:40
Source
Simply Wall Street
TradingKey Direct company coverage

Kalaris Therapeutics Inc (KLRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Kalaris Therapeutics Inc (KLRS), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for these categories for FY2019, FY2020, and FY2021 have not yet been disclosed by the company. The

Tone
Positive 72/100
Event
Earnings
Published
19 Jun 2026 15:09
Source
TradingKey
TradingKey Direct company coverage

Kalaris Therapeutics Inc (KLRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Kalaris Therapeutics Inc (KLRS), detailing its price momentum, support and resistance levels, and insights from various technical indicators and moving averages. The stock currently trades between a resistance of $5.54 and support of

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 21:09
Source
TradingKey
TradingKey Direct company coverage

Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Kalaris Therapeutics Inc (KLRS). It indicates that the company has not distributed any dividends in the past five years but has a significant 23-to-1 merger-related stock split scheduled for January 10, 202

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 00:40
Source
TradingKey
TradingKey Direct company coverage

Kalaris Therapeutics Inc (KLRS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Kalaris Therapeutics Inc (KLRS) has an earnings forecast score of 8.75, ranking high in the Biotechnology & Medical Research industry. Analysts have set an average price target of $20.00, with varying highs and lows, and largely recommend a "Buy" for the stock. The company's prev

Tone
Positive 77/100
Event
Earnings
Published
17 Jun 2026 20:40
Source
TradingKey
The Manila Times Direct company coverage

Kalaris to Present at Clinical Trials at the Summit 2026

Kalaris Therapeutics, Inc. announced it will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose results from treatment-naïve patients with Neovascular Age-Related Macular Degen

Tone
Positive 70/100
Event
Earnings
Published
17 Jun 2026 02:09
Source
The Manila Times
Investing.com Direct company coverage

TD Cowen initiates Kalaris stock coverage with buy rating

TD Cowen initiated coverage on Kalaris Therapeutics Inc. (NASDAQ:KLRS) with a buy rating, highlighting its differentiated anti-VEGF treatment TH103 and a potential $15 billion market opportunity. Analysts have set price targets ranging from $7 to $25. Despite a previous trial pau

Tone
Positive 76/100
Event
Analyst action
Published
15 Jun 2026 19:40
Source
Investing.com
GuruFocus Direct company coverage

KLRS Initiates Coverage On by TD Cowen -- Rating Set to Buy

TD Cowen has initiated coverage on Kalaris Therapeutics (KLRS) with a Buy rating, noting the company's focus on developing therapeutics for retinal diseases. Despite a low GF Score™ of 14/100 indicating potential profitability challenges, the company has a strong financial streng

Tone
Positive 76/100
Event
Analyst action
Published
15 Jun 2026 18:37
Source
GuruFocus
Stock Titan Direct company coverage

First-in-human TH103 eye trial data to be presented at Las Vegas summit

Kalaris Therapeutics (Nasdaq: KLRS) will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026 in Las Vegas. The presentation will detail single ascending dose results from treatment-naïve patients with neovascular age-related macul

Tone
Positive 64/100
Event
Earnings
Published
13 Jun 2026 07:10
Source
Stock Titan
Stock Titan Direct company coverage

KLRS SEC Filings - Kalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for investors to access Kalaris Therapeutics Inc. (KLRS) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, and 8-K material event disclosures. Recent filings cover the re-election of directors, ratification of auditor

Tone
Neutral 50/100
Event
Earnings
Published
12 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Kalaris Therapeutics (KLRS) director receives 9,000-stock option grant

Kalaris Therapeutics director Srinivas Akkaraju was granted options to buy 9,000 shares of common stock on June 3, 2026, with an exercise price of $4.72 per share. These options will vest in full on the earlier of June 3, 2027, or the company’s 2027 Annual Meeting of Stockholders

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 04:09
Source
Stock Titan
Stock Titan Direct company coverage

Kalaris Therapeutics (KLRS) director awarded 9,000 stock options

Kalaris Therapeutics director Anthony P. Adamis has been granted 9,000 stock options with an exercise price of $4.72 per share and an expiration date of June 2, 2036. These options are scheduled to vest fully by June 3, 2027, or the company's 2027 annual meeting, contingent on hi

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 03:38
Source
Stock Titan
Stock Titan Direct company coverage

Kalaris Therapeutics (KLRS) holders elect board, choose annual say-on-pay

Kalaris Therapeutics, Inc. (KLRS) announced the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Shareholders elected three directors, Napoleone Ferrara, David Hallal, and Leone Patterson, with strong support. Furthermore, they approved the advisory vote o

Tone
Neutral 50/100
Event
Earnings
Published
04 Jun 2026 20:08
Source
Stock Titan